(Q36320632)

13 August 2017

1 reference

title

An approach to evaluating drug-nutrient interactions (English)

1 reference

13 August 2017

Cristina A Santos

1

1 reference

13 August 2017

Joseph I Boullata

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

25

1 reference

13 August 2017

issue

12

1 reference

13 August 2017

page(s)

1789-1800

1 reference

Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Influence of diet and nutritional status on drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Effects of obesity on pharmacokinetics implications for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Effect of diet on vascular reactivity: an emerging marker for vascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Aprepitant--a novel NK1-receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Emtricitabine (FTC) for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Emtricitabine: an antiretroviral agent for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Gefitinib Therapy for Advanced Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Natural health product interactions with medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Bortezomib treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Effect of calcium carbonate on bioavailability of orally administered gemifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Biotin catabolism is accelerated in adults receiving long-term therapy with anticonvulsants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Muscle pain associated with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Targeting epidermal growth factor receptor--are we missing the mark?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Epidermal growth factor regulation of system L alanine transport in undifferentiated and differentiated intestinal Caco-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Gatifloxacin, Gemifloxacin, and Moxifloxacin: The Role of 3 Newer Fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.12.1789

10.1592/PHCO.2005.25.12.1789

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference